On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Axiall Corporation (NYSE:AXLL), Levy Aquisition Corp. (NASDAQ:LEVY), Exact Sciences Corporation (NASDAQ:EXAS), IGI, Laboratories, Inc. (NYSEMKT:IG)
Axiall Corporation (NYSE:AXLL), with shares gained 5.52%, closed at $46.63.
Levy Aquisition Corp. (NASDAQ:LEVY), with shares jumped 5.44%, settled at $12.21.
Exact Sciences Corporation (NASDAQ:EXAS), with shares climbed 5.44%, and closed at $22.49.
IGI, Laboratories, Inc. (NYSEMKT:IG), surged 5.41%, and closed at $8.77.
Latest NEWS regarding these Stocks are depicted underneath:
Axiall Corporation (NYSE:AXLL)
Formerly on March 3, The Board of Directors of Axiall Corporation (AXLL), declared a regular quarterly dividend of 16 cents per share of ordinary stock. The dividend is payable April 10, 2015, to shareholders of record at the close of business on March 27, 2015.
Axiall Corporation manufactures and markets chemicals and building products in the United States and internationally. The corporation operates through three segments: Chlorovinyls, Building Products, and Aromatics.
Levy Aquisition Corp. (NASDAQ:LEVY)
Levy Attainment Corp. (LEVY), and Del Taco Holdings, Inc., declared that Del Taco has closed its formerly declared recapitalization, in advance of the planned attainment of the Corporation by LAC. Restaurateur Larry Levy, the CEO and Chairman of the Board of LAC, together with his family and a group of new investors have made a private investment of $120 million in the ordinary stock of Del Taco and now own about 46% of Del Taco. Mr. Levy has assumed the Chairmanship of Del Taco while Ari Levy and Steve Florsheim, both officers and directors of LAC, have also joined the Del Taco Board of Directors.
With the completion of the recapitalization, Del Taco has eliminated its subordinated debt and reduced its total debt together with the associated cost of borrowing.
Levy Attainment Corp. does not have noteworthy operations. It intends to complete a business combination with an operating corporation in the restaurant and hospitality sectors.
Exact Sciences Corporation (NASDAQ:EXAS)
Formerly on March 13, Exact Sciences Corporation (EXAS), declared that, in support of the Corporation’s continued growth plans, it has issued restricted stock units covering a total of 125,661 shares of ordinary stock to 166 new non-executive employees under its formerly declared inducement grant program. The restricted stock unit awards vest in four equal annual installments starting on the first anniversary of the grant date. The Corporation is making this declaration as required by NASDAQ rules.
Exact Sciences Corporation, a molecular diagnostics corporation, focuses on developing non-invasive colorectal cancer screening products. The corporation develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer.
IGI, Laboratories, Inc. (NYSEMKT:IG)
IGI, Laboratories, Inc. (IG), declared it has presented its first abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Corporation’s total number of ANDA submissions now pending at the FDA to twenty-three.
Jason Grenfell-Gardner, President and CEO of the Corporation, commented, “On March 2, 2015, we committed to file at least twenty ANDAs in 2015. We believe the ANDA filed recently has an addressable market of $20 million based on January 2015 data from IMS Health. We believe our current pipeline of submissions, exclusive of partnered submissions, pending approval by the FDA now has a combined addressable market of over $623 million based on January 2015 data from IMS Health.”
IGI Laboratories, Inc., a specialty generic pharmaceutical corporation, develops, manufactures, and markets topical formulations in the United States. It sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms under IGI label.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
